An allotypic form of the low affinity IgG Fc receptor Fc gamma RIIa (CD32), termed low responder (LR) because of its weak reactivity with mouse (m) IgG1, interacts efficiently with human (h) IgG2. Fc gamma RIIaLR is the first known human FcR that binds this IgG subclass. In this study, we analyzed the role of Fc gamma RIIa in binding of stable hIgGsubclass dimers, and in induction of T cell mitogenesis using chimeric anti-CD3 mAb. We demonstrate that the functional polymorphism to hIgG2 is expressed on the majority of Fc gamma R-bearing peripheral blood cells: monocytes, neutrophils, and platelets. We were able to assess Fc gamma RII-mediated IgG-binding without interference of other Fc gamma R-classes, by blockade of Fc gamma RI on monocytes, and by using neutrophils of an individual deficient for the Fc gamma RIIIB gene. This study indicates as subclass specificity: hIgG3 >hIgG1,hIgG2 >> hIgG4 for Fc gamma RIIaLR and hIgG3,hIgG1 >> hIgG2 > hIgG4 for Fc gamma RIIaHR. Comparing the serum hIgG levels of individuals homozygous for the two fc gamma RIIa allotypic forms, we observed significantly lower hIgG2 serum levels in individuals expressing the hIgG2-binding LR allotypic form. This observation may implicate that Fc gamma RIIa regulates hIgG subclass production or turnover in man.
Introduction
Receptors specific for the Fc moiety of IgG (FcyR), expressed on a broad range of hematopoietic cells, create an important linkage between humoral and cellular defence mechanisms. forms, and differential expression on distinct cells may have major consequences for antibody effector functions. FcyRII is known to be polymorphic with respect to its interaction with mouse (m) IgG I complexes (4, 1 1 ). It was recently shown that this functional polymorphism resides in a single Arg-His amino acid change at position 131 in FczyRIIa (12) (13) (14) . Excitingly, it was found that this change also has implications for the interaction with hIgG: transfected fibroblasts expressing FcyRIIa (131-His), which was termed low responder (Fc-yRIIaLR) because of its weak reactivity with mIgGl, appeared to bind hIgG2 dimers efficiently, in contrast to the Fc-yRIIa high responder (FcyRIIaHR) allotypic form ( 13) .
Recently, we developed a matched set of mouse/human chimeric anti-CD3 mAb ( 15) . mAb directed against the multimolecular TcR/CD3 complex on the cell surface of human T cells, are capable ofinducing T cell activation, both in vitro and in vivo ( 16) . Accessory cells such as monocytes, however, are required to induce full activation and proliferation of the T cells and provide crosslinking of the anti-CD3 mAb via Fc receptors, as well as production of lymphokines such as IL-1 (1 1, 17) . Using these antibodies, we demonstrated that this Fc-yRII polymorphism is functionally expressed in anti-CD3 mAb induced T cell activation, both with monocytes and FcyRIIaHR_ or FcyRIIaLR transfected fibroblasts as accessory cells ( 18) .
A complication in linking the above observations to other cells expressing Fc-yRII is the potential coexpression of multiple isoforms of FcyRII, such as FcyRIIb, which expresses a distinct subclass specificity ( Winkel, and P. J. A. Capel. Submitted for publication), and coexpression of members of different FchyR classes on most blood cells (4) . Furthermore, studies with hybrid antibodies have suggested that one IgG molecule may simultaneously interact with two distinct Fc'yR molecules ( 19) , this might imply that potential cooperation between different classes of Fc-YR molecules may affect IgG binding avidity. We now demonstrate the functional Fc'yRIIa polymorphism for hIgG2 complexes on the majority of FcyR bearing peripheral blood cells: monocytes, neutrophils, and platelets. Comparing IgG serum levels between groups of individuals homozygous for either FcyRIIa allotype, we found significantly lower serum hIgG2 levels in FcyRIIaLR individuals. This observation may implicate that FcyRIIaLR, which is the first FcR known to bind hIgG2 efficiently, may be involved in modulation of hIgG serum levels.
Methods
Monoclonal antibodies. Hybridoma cell line CLB-T3 /4. 1, producing a mIgGlK mAb reactive with thee chain ofthe TcR/CD3 complex (20) and its heavy chain isotype variants have been described in detail (15, 21) .
Anti-Fc'yRI mAb 197 (y2asK) and mAb 22 ('Y1,K; FITC-conjugated), anti-Fc'yRII mAb IV.3 ('y2bK) and anti-FcyRIII mAb 3G8 ('y1,K) were kindly provided by Medarex, Inc. (W. Lebanon, NH). Anti-FcyRII mAb 41H16 ('y2asK) was provided by Dr T. Zipf(University of Texas, Houston, TX), and anti-FcyRIII mAb CLB GranI ('y2aK) was from the CLB. Anti-CD28 mAb CLB-CD28/ 1 ('y1,K) was provided by Dr R. van Lier (CLB, Amsterdam).
Purification ofPBC. T cells were isolated by sheep E-rosette sedimentation from PBMC, obtained by Percoll density centrifugation from buffy coats, as described in ( 15 ) . Residual monocytes were removed by plastic adherence. T cell purity was checked by measuring LPS-induced monocytic IL-6 production (22) , which was found < 5 pg/ml IL-6 in an overnight incubation of 200,000 cells/ml, whereas unseparated PBMC produced 2,000 to 10,000 pg/ml. Monocytes were isolated from PBMC by counterflow centrifugation, as described elsewhere (23), and were > 95% pure, as determined in cytocentrifuge preparations after staining for nonspecific esterase, and May Grtinwald-Giemsa.
Granulocytes were separated from PBMC and platelets by centrifugation of trisodium citrate (14 mM) anticoagulated blood on 1.076 g/ml Percoll. Erythrocytes were removed from the granulocyte pellet by lysis in isotonic NH4C1 on ice, resulting in a PMN preparation containing > 95% neutrophils (24) . Induction of PMN-FcyRI was analyzed after incubation of cells in culture medium (see below) supplemented with 300 U/ ml IFN-y (Genentech, San Francisco, CA), inhibition analyses of IFN-'y induced effects were performed by supplementing inhibitory anti-IFN-'y mAb MD-1 ( 10 tg/ml) (25).
Platelet-rich plasma was obtained by centrifugation ( 15 min, 250 g) of EDTA (5 mM) anticoagulated blood. Platelets were then concentrated by centrifugation (7 min, 1,200 g) and three washes were performed with PBS/5 mM EDTA/0.5% FCS (26) . PMN expressing reduced levels of FcyRIII were isolated from two patients with diagnosed paroxysmal nocturnal hemoglobinuria (PNH) (27, 28) . The neutrophil preparations from these patients contained -80% and -100% of (GPI-linked) FcyRIIIb deficient cells, respectively, and expressed -10% of normal Fc'YRIIIb levels. FcyRIIIdeficient (Fc-yRIIIOe) PMN were isolated from an FcyRIIIB-deficient donor. The absence ofthe FcyRIIIB gene, Fc'yRIIIb mRNA, and soluble FcyRIIIb in serum was previously demonstrated in a study by Huizinga et al. (29) . PMN from this FcyRIIIb "* donor showed a complete absence ofFcyRIII expression in immunofluorescence studies (see Results; Fig. 4 B) .
GPI-PLC treatment. FcoyRIIIb was removed from normal PMN by incubation with GPI-specific phospholipase C (GPI-PLC). PMN were washed and incubated for 1 hat 370C in Iscove's modified Dulbecco's medium (IMDM) supplemented with a 1:1,000 dilution of GPI-PLC. GPI-PLC isolated from Bacillus thuringiensis was kindly provided by Dr. T. Schumacher (Netherlands Cancer Institute, Amsterdam).
T cell proliferation assay. Highly purified T cells were stimulated with graded amounts of anti-CD3 mAb in 200 I1 IMDM, supplemented with 5% heat-inactivated pooled human serum, 50MgM 2-mercaptoethanol, 100 IU/ml penicillin, and 100 ,g/ml streptomycin. All incubations were performed in the presence of 1 Mg/ml anti-CD28 mAb as a T cell costimulus (18) . Without accessory cells, no T cell proliferation was observed by the anti-CD28/anti-CD3 mAb combination alone. As accessory cells, either 60,000 PMN or 2 x I0' platelets were added per well. To generate optimal T cell triggering, we first titrated PMN in anti-CD3-induced T cell proliferation experiments using an optimal amount of anti-CD3 mAb (40 ng/ml). Remarkably, the optimum for mIgGl anti-CD3 induced proliferation was reached by supplementing -30,000 PMN per well, whereas the potency of hIgG2 anti-CD3 induced T cell proliferation still increased significantly up to PMN concentrations of -60,000 cells per well (observed in five experiments using cells from different donors). Since this increase of PMN-density did not affect the mIgGl anti-CD3 induced mitogenicity, further experiments were performed using -60,000 PMN per well.
Titration of platelet concentration in the presence of an optimal amounts of anti-CD3 mAb, revealed an optimal T cell proliferation at a density of 2 X 105platelets per well.
Inhibition by anti-Fc-yR mAb was assessed by incubation of T cells with an optimal amount ofanti-CD3 mAb (40 ng/ml) in the presence ofeithermAb 197 (20,gg/ ml), mAbIV.3 (5 Mg/ml), mAb CLB Gran I (10 ,ug/ml), CLB Granl F(ab')2 fragments (20 ,ug/ml), ormAb 3G8 (20 ,ug/ml). These inhibitory mAb were preincubated for 1 h with accessory cells before purified T cells were added to the cultures. A 4-h [3H1thymidine (0.2 ,Ci/well) incorporation assay was performed on day 4. All incubations were performed in triplicate, and SD were always < 10%.
We performed control experiments to check for (nonspecific) effects of anti-FcyR mAb on anti-CD3 induced T cell proliferation, (via potential activation and subsequent degranulation of PMN) during culture. Anti-FcyR mAb were added to an FcyR-independent T cell activation system (30) . In this assay, mIgA anti-CD3 mAb were coated at high density to culture wells; a condition inducing potent proliferation of purified T cells (this mIgA mAb is a heavy chain isotype switch variant (21) of the anti-CD3 mAb used in rest of our studies). No inhibitory effects of any anti-FcyR mAb were observed in this system. Purification of IgG paraproteins. Purified hIgG subclass proteins with kappa light chains were isolated from sera of patients with multiple myeloma by (NH4)2S04 precipitation and DEAE-Sephadex (Pharmacia, Uppsala, Sweden) ion-exchange chromatography. If necessary, proteins were furtherpurified onprotein A or anti-hIgG subclass Sepharose. All preparations were checked for impurities and IgG subclass content in immunoelectrophoresis, radial immunodiffusion, and hemagglutination assays (31, 32) . The hIgG paraproteins used in this study were > 98% pure, as evaluated with these methods. Purified hIgG was either used in a monomeric form, after removal of aggregates by ultracentrifugation ( 1 h at 150,000 g), or as stable dimeric complexes (see below).
Dimer binding studies. Purified IgG paraproteins were incubated overnight with F(ab')2 fragments of a mouse anti-human K-light chain mAb K35, in a molar ratio of 1:1, which resulted in stable tetrameric complexes, as detailed in (24) . Human monocytes (3 X I0 in 100 ;l PBS/ 1% BSA) were incubated with 25 Ml of anti-Fc'yR mAb 197 (7 Mg/ml) and 25 Ml ofan optimal amount ofhIgG dimers ( 25,g/ml) for 45 min at 40C. The amount of mAb 197 was optimized to result in complete blockade of both monomeric IgG binding to FcyRI, and Fc-yRI-mediated EA-rosetting (see below). After washing, cells were subsequently incubated with FITC-conjugated F(ab')2 fragments of goat anti-hMg antiserum (Cappel, Cochranville, PA), and FITC-conjugated F(ab')2 fragments of rabbit anti-goat antiserum (Cappel), each for 45 min at 40C. Cell-bound hIgG dimers were detected flow cytometrically by a FACScanO (Becton Dickinson Immunocytometry Sys., Mountain View, CA). To remove crossreactive antibodies, all FITCconjugates were absorbed with mIgG-coated Sepharose beads prior to use. Statistical analysis was performed using a Student's t test.
Dimer binding to PMN was essentially performed as detailed above, but without addition of mAb 197. Since hIgG4 dimers did not bind to FcyRII of either monocytes or PMN of any donor tested, we checked the integrity ofthis binding reagent by assessing dimer binding to U937 cells, which were incubated with IFN-y (300 U/ml overnight) before use to enhance Fc-yRI expression (1).
EA-rosetting; specificity of inhibitory anti-FcyRI and anti-Fc-yRII mAb. To check for specific inhibition by anti-FcyRI and anti-FcyRII mAb in our assays, we tested these mAb in EA-rosetting experiments. Two types of indicator erythrocytes were used: rhesus-D positive human erythrocytes were optimally sensitized either with a human antiserum directed against rhesus-D (EA-hIgG; Merz and Dade, Dudingen, Switzerland), or with a mIgGi anti-glycophorin A mAb (EA-mIgGl) (23, 33) . Rosetting was scored microscopically as described before (33) .
Inhibition of FcyRIor FcyRII-mediated IgG-binding was performed by adding mAb 197 (7 ;g/ml) or mAb IV.3 (2.5 ug/ml), respectively. Both antibodies were used at concentrations that inhibited specific EA-rosetting via FcyRI or FcyRII using purified monocytes and EA-hIgG or EA-mIgG1, respectively (23, 33). Rosettes were readily observed after incubation of monocytes with EA-hIgG: 70±3% of cells were scored positive (n = 3). Formation of rosettes was not inhibited by addition of mAb IV.3 (73±4% rosetting cells; n = 3), in contrast to mAb 197, which blocked EA-hIgG rosetting efficiently (2±2% rosettes; n = 3). FcyRII-mediated rosetting was measured by adding EA-mIgGI to HR monocytes, which resulted in 58±3% rosettes (n = 3). Addition of identical concentrations of the blocking anti-Fc'yR mAb as above, resulted in efficient inhibition of EA-mIgGI rosetting by mAb IV.3 (3±1% rosettes; n = 3), whereas mAb 197 did not significantly impede rosette formation (56±2% rosettes; n = 3). We next evaluated whether FcyRI was efficiently blocked by preincubation with mAb 197 and, therefore, could be used to study specific binding to Fc'yRIIa on monocytes. Monocytes were first incubated for 30 min at 37°C in RPMI 1640 medium (without serum) to remove cytophilic IgG. Cells were washed twice in medium and incubated for 15 min at 4°C in PBS/0.5% BSA/0.1% NaN3 alone, or supplemented with either anti-FcyRI mAb 197 (7 jg/ ml) or mAb IV.3 (2.5,ug/ml). Subsequently, 10 gg/ml of monomeric hIgG was added, and after a 45-min incubation at 4°C, cells were washed. Cell-bound hIgG was detected flow cytometrically by a FACScanO, using FITC-conjugated F(ab')2 fragments of goat anti-hIgG antiserum (Cappel). Addition of monomeric hIgG to monocytes resulted in 79±3% positive staining cells (n = 2), which was effectively blocked by preincubating the cells with mAb 197 (4±2% positive cells; n = 2), but not with mAb IV.3 (70±4% positive cells; n = 2). Measurement ofserum IgG. Sera and citrated blood samples were collected by venipuncture from 69 randomly selected volunteering colleagues, 43 FcyRII phenotyping. The FcyRIIa phenotype of cells from different donors was analyzed by comparing the potency of mIgG1 and hIgG2 anti-CD3-mAb induced T cell proliferation in PBMC isolated from citrated blood, as detailed in (18) . Briefly, 40,000 PBMC were cultured for 4 d in culture medium (see above) after addition of either mIgGl, or hIgG2 anti-CD3 mAb in an optimal concentration (40 ng/ ml). As described before (18) , three groups ofdonors could be discriminated: two groups with PBMC only responsive to either mIgGl, or hIgG2 anti-CD3 mAb, and one group with a comparable reactivity to both anti-CD3 mAb, indicating homozygous Fc-yRIIa"', homozygous Fc'yRIIa'L, and heterozygous FczyRIIaLR.HR individuals, respectively.
In addition, FcyRIIa phenotypes of donors were assessed by using immuno fluorescence analysis on a FACScan using anti-FcyRII mAb 41H16 (which selectively reacts with FcyRIIaHR [34] ) and mAb IV.3 (recognizing both FcyRIIa allotypic forms), followed by detection with FITC-conjugated F(ab')2 fragments ofgoat anti-mouse antiserum (G26M17F, CLB) as described previously ( 18, 34) . To avoid cytophilic binding of the mIgG2a mAb 41H 16 to the high-affinity FcyRI, all mAb incubations were performed in the presence of 25% heat-inactivated human serum.
All experiments in this study were performed using cells isolated from either FcyRIIa'L or FcyRIIaHR homozygous donors.
Results
Human IgG dimer binding to monocytes. Human monocytes express both FcyRI and FcyRIIa constitutively (4). When used as accessory cells in anti-CD3 induced T cell proliferation, mitogenicity to chimeric hIgGl, hIgG3, and hIgG4 anti-CD3 was found to be FcyRI-mediated ( 18) . The hIgG2 anti-CD3 mAb, however, induced FcyRIIa-mediated T cell proliferation, which was only found with PBMC ofindividuals expressing the FcyRIIaLR allotypic form (both homoand heterozygotes) ( 18) . We now studied binding of well-defined stable Purified monocytes isolated from homozygous FcyRIIatyped donors, were incubated with dimeric complexes of defined hIgG subclasses. hIgG2 dimers were bound differentially by cells from FcyRIIa"' and FcyRIIaHR individuals, as illustrated in Fig. 1 A, and B , respectively. Significant binding of hIgG2 dimeric complexes was only apparent to cells bearing the FcyRIIa'L allotypic form ( Fig. 1 A) , whereas the homozygous Fc.yRIIaHR-expressing cells remained negative ( Fig. 1 B) . The same pattern of binding was observed with monocytes from nine LR and five HR donors ( Fig. 1 D) , and with four different hIgG2 myeloma proteins (data not shown). Parallel experiments were performed using hIgGI, hIgG3, and hIgG4 dimeric complexes. Both hIgGl and hIgG3 dimers bound effectively to monocytes from the two types of donors, as shown in Fig. 1 C, and 1 E, respectively. No difference was observed in hIgGl dimer binding between the homozygous FcyRIIa I and Fc'yRIIa'H monocytes ( Fig. 1 C) . Cells expressing the FcyRIIaLR allotypic form, however, exhibited a significantly higher capacity to bind hIgG3 dimers (P < 0.001; Fig. 1 E) . In none of the experiments performed we observed binding of hIgG4 dimers to FcyRI-blocked monocytes. The percentage of cells with fluorescence above background was always < 2%, both with monocytes from FcyRIIaLR (n = 15), and FcyRIIa' (n = 8) individuals. To appraise the validity of the hIgG4 dimeric complexes as binding reagents, we performed binding experiments with U937 cells (expressing FcyRI and FcyRIIaHR [8] ). Upon incubation of these cells with hIgG4 dimers, 99% ofthe U937 cells stained positive, which could be inhibited by mAb 197 (6% positive cells), but not by mAb IV.3 (99% positive cells) (n = 2). This susceptibility ofhIgG4 binding to inhibition solely by anti-FcyRI mAb 197 indicates, furthermore, that FcyRIIa on U937 is incapable of interacting with hIgG4 dimers (as observed with monocytes).
The functional FcyRIIa polymorphism to hIgG2 is expressed on platelets. A substantial portion ofFcyRII present on PBC is expressed on platelets. Platelets do not express other classes of FcyR (35) , and seem therefore a superb model system to study FcyRII-IgG interactions. Consequently, we studied anti-CD3-induced T cell activation in the presence ofplatelets as accessory cells. In contrast to T cell mitogenesis studies with monocytes as accessory cells, addition of anti-CD3 mAb to platelets alone was insufficient to induce T cell proliferation. Platelets apparently lacked the ability to provide an accessory signal for full activation of T cells. We circumvented this requirement by adding an anti-CD28 mAb as costimulator to the incubations. Addition of anti-CD28 mAb alone or anti-CD28 combined with the anti-CD3 mAb CLB-T3/4 did not result in prolifera- tion of purified T cells. Platelets, isolated from homozygous FcoyRIIaHR or FcyRIIaLR individuals were used to study T cell proliferation induced by quantitated amounts of mIgGl or hIgG2 anti-CD3 mAb (shown in Fig. 2 C and D) . Platelets derived from an FcyRIIa'L individual supported hIgG2 anti-CD3-induced proliferation efficiently, whereas mIgGl induced proliferation was hardly detectable (Fig. 2 C) . Platelets isolated from FcyRIIa"' individuals were observed to support mIgGl anti-CD3-induced T cell mitogenesis, but not hIgG2 anti-CD3 induced activation. Addition of mAb IV.3 to these cultures resulted in complete inhibition of both hIgG2 and mIgGl anti-CD3-induced T cell mitogenesis (> 99% inhibition; n = 2). Platelets expressing the FcyRIIa'L allotypic form, furthermore supported induction of T cell proliferation by hIgGl anti-CD3 efficiently, but not with hIgG3, or hIgG4 (n =2).
Interaction between (chimeric) anti-CD3 mAb and FcyR on PMN. Human neutrophils constitutively express both FcyRIIa and a GPI-linked form of FcyRIII; i.e., FcyRIIIb. Fc'yRIII has been implicated in modulation of FcyRII affinity and triggering (36) (37) (38) . To examine this in more detail, we studied antibody-FcyR interactions on normal PMN and PMN impaired in expression of FcyRIIIb. PMN were isolated from healthy donors homozygous for either FcyRIIa phenotype, and they were used as accessory cells in anti-CD3-induced T cell activation experiments, as shown in Fig. 3 . In these experiments, we also added anti-CD28 mAb as a T cell costimulus, since anti-CD3 mAb combined with PMN alone were incapable ofinducing T cell proliferation. A dose-dependent mIgGl anti-CD3 mAb induced T cell activation was only observed using PMN expressing FcYRIIaHR, whereas hIgG2 anti-CD3 mAb preferentially induced proliferation in the presence of FcyRIIaLR PMN. Cells from both types of individuals supported proliferation with hIgGl anti-CD3, but not hIgG3 or hIgG4 subclass variants (Fig. 3) . Evaluation of the role of FcyRII in these responses is complicated by expression of both FcyRIIa and FcyRIIIb on these cells. Inhibition analyses were, therefore, performed on normal and on FcyRIIIb negative (FcyRIII ¶eg) PMN.
Phenotypes of PMN used for these inhibition experiments were analyzed cytofluorometrically as shown in Fig. 4 A and B . The PMN analyzed in Fig. 4 B, isolated from a donor who showed a complete lack of PMN-FcyRIIIb expression caused by a genomic deletion in the FcyRIIIB locus (29) , stained positive with anti-FcyRII mAb (IV.3), but not with a FcyRIIa'specific (41H116) or anti-FcyRIII mAb (CLB Granl ). This indicated expression of the FcyRIIa'L allotypic form exclusively on these cells. Fig. 4 A shows the analysis of a normal donor matched for expression of this FcyRIIa allotypic form. PMN of both these donors, furthermore, did not express Fc-yRI, as indicated by absent staining with anti-FcyRI mAb 197, and 22 (data not shown).
To evaluate which FcyR classes were involved in anti-CD3 induced T cell mitogenesis in the presence of PMN, we analyzed T cell proliferation in this system, in the presence or absence of blocking anti-FcyRI ( 197), anti-FcyRII (IV.3), or anti-FcyRIII (CLB Granl ) mAb. Inhibition patterns of anti-CD3 induced T cell proliferation by these anti-FcyR mAb are shown in Fig. 4 Anti-CD3 mAb concentration (ng/ml) FcyRIIIn`donor (analyzed in Fig. 4 D) , also showed complete susceptibility of hIgG2 anti-CD3-induced T cell mitogenicity to mAb IV.3, similar to FcyRIIaLR-bearing PMN from all normal donors evaluated (n = 12). In contrast, hIgGl anti-CD3induced T cell proliferation was strongly inhibited after blockade ofFcyRIIIb (Fig. 4 C) . Surprisingly, however, the absence of FcyRIIIb did not affect the ability of FcyRIIIbn" PMN to support T cell mitogenesis induced by this hIgG subclass. The data shown in Fig. 4 D suggested this proliferation-induction to be partly FcyRII mediated, supported by a decrease in T cell responsiveness after addition ofmAb IV.3. Remarkably, a synergistically increased inhibition was observed by combining mAb IV.3 with mAb 197. Indeed, a complication in these culture experiments may be induction ofFcyRI on PMN by IFN-'y ( 1 ) , produced by proliferating T cells, which may then mediate binding ofhIgGl mAb. We tested this hypothesis by analyzing cells from the cultures cytofluorometrically, using a FHTC-conjugate of anti-FcyRI mAb 22, as shown in Table I. After gating on PMN, we found a significant increase ofFcyRI expression after culturing the cells overnight, provided anti-CD3-stimulated T cells were present in the culture. The level of FchyRI expression on these PMN was similar to the expres- Turning our attention to FcyRIIIb, we observed a dramatic decrease in the expression level of this FcyR on PMN measured during the first 2 d of culture (n = 3), as indicated in Table II . The presence of soluble FcyRIII in the supernatants (data not shown) indicated that FcyRIIIb is shed from the cell membrane during culture (39) . As a control, we stained cells with a (granulocyte-specific) CD66 mAb, CLB Gran 10, which revealed all gated cells to be positive, without reduced fluorescence. The observation that FcyRI is rapidly induced during culture, while FcyRIIIb expression on the cell surface is decreased, might implicate a minor role for FcyRIIIb in hIgGl anti-CD3 induced T cell mitogenesis. Expression of Fc'yRI, furthermore, posed a practical difficulty in that anti-FcyRIII mAb CLB Gran 1 (mIgG2a subclass) may inhibit binding to Fc'yRI via its Fc-moiety. We, therefore, used CLB Granl F(ab')2 fragments and mAb 3G8 (mIgGl subclass) in inhibition analyses, which did not (CLB Granl [Fab']2) or weakly (mAb 3G8) affect hIgG1 anti-CD3-induced T cell activation.
Human IgG dimer binding by normal and FcyRIII"9 PMN. We analyzed binding of dimeric hIgG subclass complexes to PMN, with normal, and absent expression of FchyRIIIb. Cells of a normal FcyRIIa'u homozygous donor and the Fc'yRIIIbn* donor described above were incubated with optimal amounts ofdimers ( Fig. 5 ). 5 C and 5 D indicate that PMN of both donors were capable of binding hIgG2 dimers, which was completely inhibitable by adding mAb IV.3. PMN of both types of donors, furthermore, bound hIgGl and hIgG3 dimers efficiently ( Fig. 5 A, B , E, and F, respectively), although the binding capacity of normal PMN for dimers of these isotypes were significantly higher. On normal PMN, the major component of this binding was FcyRIIIb-mediated, indicated by susceptibility to inhibition by anti-FcyRIII mAb 3G8 ( Fig. 5 A and E). The low amount of hIgGl /hIgG3 binding observed in the presence of mAb 3G8, was decreased to background level when this mAb was combined with mAb IV.3 (data not shown; n = 2). The experiment with FcyRIIlbnl* PMN showed that, even in the absence of 11.4 hIgG1 anti-CD3 + T cells + Anti-IFN-'y 9.5 * Freshly isolated PMN were cultured overnight in culture medium supplemented with the indicated agents in the presence or absence of highly purified T cells. $ PMN were washed and incubated with a FITC-conjugate of anti-FcyRI mAb 22. After gating on PMN, the percentage of cells displaying fluorescence intensities above background level (PMN incubated in buffer without mAb 22-FITC) was assessed. § As a control, the cells were stained with granulocyte-specific CD66 mAb CLB Gran 1O, which showed all gated cells to be positive. fragments of a goat anti-mouse antiserum. The percentage of cells, displaying fluorescence intensities above background level, and mean fluorescence intensities of the cell-population (between parentheses) are indicated. § As a control, PMN were stained with CD66 mAb CLB Gran 10, which showed all cells to be positive.
Fc'yRIIIb, PMN were still capable of binding significant amounts ofhlgGl and hIgG3. This binding, however, was now completely susceptible to blockade by mAb IV.3 ( Fig. 5 B and  F) , and, hence, FcyRII-mediated. Binding of hIgG4 dimeric complexes to these cells was also studied, but none ofthe PMN preparations evaluated in our laboratory (n = 15), was capable of significantly binding this hIgG subclass ( Fig. 5 G and H) . Comparing hIgG2 dimer binding to normal PMN, homozygously expressing the LR or HR allotypic form of FcyRIIa, we observed a similar pattern as on monocytes. Efficient binding was only apparent on PMN expressing FcyRIIaLR (31 ± 15% positive cells; n = 12), whereas FcyRIIaHR homozygous PMN bound hIgG2 poorly (7±4% positive cells; n = 12). Incubation of PMN with GPI-PLC, which resulted in removal of -90% of the GPI-linked FcyRIIIb, did not significantly affect the ability of these cells to bind hIgG2 (n = 3). hIgG2 dimer binding studies were, furthermore, performed with PMN isolated from two patients suffering from PNH, which is an acquired disorder resulting in strongly diminished expression of GPI-linked membrane proteins, such as FcyRIIIb (27, 28) . PMN of both these patients were found to express FcayRIIaHR only, and interacted weakly with hIgG2 dimers (resulting in 4 and 8% positive staining cells, respectively).
Correlation between Fc-yRIIa polymorphism and donor hIgG2 serum levels. The FcyRIIaLR allotypic form seems unique in its ability to bind hIgG2, since no other hFcYR has been reported to interact efficiently with this isotype ( [4, 10] , this study). It has been postulated that so-called Ig binding factors (most likely soluble FcyR) may affect Ig production and proliferation of B cells (40) . This prompted us to analyze hIgG subclass levels in sera of healthy donors. We randomly analyzed 69 donors, of whom 10 were found homozygous for FczyRIIaHR, and 22 for FcyRIIaLR. Fig. 6 A shows the total hIgG contents measured in the sera of these 32 homozygous donors. Comparing the two groups ofindividuals, we found no significant differences in total hIgG concentrations. Remarkably, a striking difference was found for hIgG2 subclass levels, which were calculated relative to the hIgG 1 concentration, to correct for variations in total hIgG serum levels between different individuals (indicated in Fig. 6 A) . As shown in Fig. 6 ferences between the two groups were also found by calculating hIgG2 (P = 0.05) and hIgG1 (P = 0.008) levels relative to total hIgG concentration. In these analyses, hIgG2 levels were found decreased while hIgG I levels appeared increased in FcyRIIaLR versus FcyRIIaHR donors. Absolute hIgGl and hIgG2 levels, however, did not differ significantly. No significant differences were observed in hIgG3 or hIgG4 serum levels. If hIgG2 is more efficiently cleared by the LR compared to the HR allotypic form of FcyRIIa, then also heterozygous individuals might be expected to have lower relative hIgG2 subclass levels compared with homozygous FcyRIIaHR donors. Comparing the hIgG2/hIgGl ratio between the three groups, we found that this ratio (mean±SEM) of heterozygotes (0.54±0.04) was intermediate between the ratio of HR (0.67±0.05) and LR homozygotes (0.50±0.04). The difference between the heterozygotes and HR homozygotes was statistically significant (P = 0.04), whereas the difference between heterozygotes and LR homozygotes was not.
Discussion
Recently, it was shown that the classical polymorphism of hFcyRIIa, as originally defined in mIgG 1 anti-CD3-induced T cell mitogenesis (4, l 1 ), has profound implications for hIgG2 binding. Transfected fibroblasts expressing the FcyRIIaLR allotypic form were found to interact efficiently with this hIgG subclass, in contrast to FcyRIIaHR-transfected cells ( 13) . T cell mitogenesis experiments using hIgG2 anti-CD3, furthermore, indicated that differential binding of hIgG2 was inherent to normal monocytes, and was correlated with FcyRIIa phenotype ( 18) .
In the present study we demonstrate that the functional FcyRIIa polymorphism is expressed on monocytes, PMN, and platelets. We studied this in two systems: first, by binding analyses with stable dimeric hIgG complexes, and secondly, in anti-CD3-induced T cell proliferation in which large, heavily opsonized complexes were presented to FcyR. Both in hIgG dimer binding and anti-CD3-induced T cell mitogenesis, we were able to displace hIgG2 from cells with mAb IV.3, supporting FcyRIIa-mediated binding. FcyRIIa, furthermore, bound antibodies of the hIgGl and hIgG3, but not hIgG4 isotypes, as shown by dimer binding to FcyRI-blocked monocytes (Fig. 1 ). In these analyses, hIgG3 dimers were bound significantly better by FcyRIIa'L than by FcyRIIaHR. Since cross-talk between FcoyRI and II has been observed in signalling in U937 cells ( 19) , it seems possible that ligation ofFcyRI on monocytes by mAb 197 may affect binding via FcyRII. In our opinion, this is not supported by our studies with FcyRIIa-transfected fibroblasts ( 13) , which showed identical binding characteristics of IgG dimers, as shown with the FcyRI-blocked monocytes in the present study. Blocking of FcyRI by intact mAb 197 might cause problems resulting from cross-reactivity of its Fc region with other FcyR classes. All available FcyRI mAb, however, bind to an epitope outside the ligand-binding site (41 ) , and only one of them (mAb 197, as used in the present study) is inhibitory by an interaction of its mIgG2a Fc region to the Fc-yRI-binding site ("Kurlander phenomenon" [4] ). Interference in IgG dimer binding to FcyRIIa, however, seems improbable since mIgG2a has only minor affinity for this class of FcyR (4), indicated furthermore by the inability of FcyRIIa transfected fibroblasts to support mIgG2a anti-CD3-induced Functional FcyRII Polymorphism on Peripheral Blood Cells 1543 LR T cell activation ( 18) . Binding of dimers to FcyRII on PMN exhibited similar characteristics as on monocytes (Fig. 5 ). After blocking FcyRIIIb on these PMN by mAb 3G8, hIgGl and hIgG3 dimers were still binding weakly to the cells, which could be abrogated by combining mAb 3G8 with mAb IV.3. The fluorescence intensities observed with hIgGl, hIgG2, and hIgG3 dimers to PMN on which FcyRIIIb was blocked by mAb 3G8 (Figs. 5 A, C, and E) , were comparable to the staining levels observed with FcyRIII "* PMN (Figs. 5 B, D, and F) .
These data were in agreement with data from the anti-CD3-induced T cell proliferation studies. hIgG2 anti-CD3 mAb acted as a potent T cell mitogen in the presence ofmonocytes ( 18) , platelets (Fig. 2) , and neutrophils ( Fig. 3) , providing the FcyRIIa' allotypic form was expressed. hIgGl anti-CD3 mAb, in contrast, induced proliferation of T cells in the presence of accessory cells from all donors, regardless of Fc'yRIIa-phenotype. This mitogenic activity was blocked almost completely by anti-FcyRI mAb 197 (18) or anti-FcyRIII mAb CLB Granl (Fig. 4 C) when monocytes or neutrophils were used as accessory cells, respectively. Using FcyRIIa'/ FchyRIIIb"* PMN as accessory cells, we also observed an induction of T cell mitogenesis by hIgGl anti-CD3 mAb. Our observations indicate that this mitogenicity is both FcyRI-and FcyRII-mediated, suggested by low susceptibility to either mAb 197 or mAb IV.3 alone, but a synergistic inhibition by combining these anti-FcyR mAb with PMN from both types of donors. Cytofluorometric analyses ofPMN during T cell mitogenesis experiments showed, furthermore, induction ofFc'YRIexpression on PMN, which was mediated by IFN-'y, produced by activated T cells. This is supported by inhibition of Fc'yRIinduction in the presence of a neutralizing anti-IFN-y mAb. Culturing ofPMN, furthermore, affected the level ofFcyRIIIb expression, which was reduced dramatically. This observation, and the absent or weak inhibition by mAb CLB Granl F(ab')2 fragments and mAb 3G8, respectively, suggest a minor role for Fc'yRIIIb in anti-CD3-induced T cell activation. The strong inhibition by anti-FcyRIII mAb CLB Granl of hIgGl anti-CD3-induced T cell mitogenesis ( Fig. 4 C) is, therefore, most likely mediated by the Fc-moiety ofthis (mIgG2a) mAb (Kurlander phenomenon [41] ).
A possible explanation for the inhibition pattern of hIgGl anti-CD3-induced T cell mitogenesis (shown in Fig. 4 ) may be the following: hIgGl, in first instance, most likely interacts with FcyRIIIb and FcyRIIa, supported by susceptibility of hIgGl dimer binding on normal PMN to inhibition by mAb 3G8 and mAb IV.3, which results in activation of T cells. Production of IFN-'y by these activated T cells leads to induction of FcyRI. In parallel, FcyRIIIb is shed from the cell membrane. This implicates that these FcyR might be involved in hIgG 1-induced T cell mitogenicity at different time points during the culture.
Anti-CD3-induced T cell proliferation with platelets as accessory cells indicated that the FcyRIIa polymorphism to hIgG2 was also expressed on platelets. hIgG2 anti-CD3 induced T cell proliferation was only observed in the presence of Fc'yRIIal expressing cells (Fig. 2 ). The pattern of subclassspecific T cell mitogenesis in these experiments, in fact, appeared identical to T cell mitogenesis in the presence of FcyRIIa-transfected murine fibroblasts (18) . Rosenfeld et al. (42) have shown stable interdonor variation in FcyRIIa expression levels. Differences resulting from this polymorphism were controlled for in this study, by matching different donors (two FcyRIIa'Land one FcoyRIIaHR-homozygous) for Fc'yRIIa expression levels on their platelets ( Fig. 2 A and B ).
Comparing the data obtained with hIgG3 in dimer-binding and T-cell mitogenicity studies, an inconsistency was found:
hIgG3-and hIgGl-dimers both bound FcyR positive cells efficiently, whereas the hIgGl chimeric mAb was superior to hIgG3 in inducing T cell mitogenesis. In the present and previous studies, we have observed that hIgG3 anti-CD3 mAb, in contrast to hIgGI anti-CD3, were poor T cell mitogens when accessory cells from most healthy donors were used ( 15, 18) . This was observed for two different allotypic forms of hIgG3 ( 15) . Strikingly, we observed no differences in cytophilic binding ofhIgGl and hIgG3 anti-CD3 mAb to IFN-'y treated U937 cells (P. Parren, unpublished results). Similar observations were reported by Bruggemann et al. (43) and Steplewski et al. (44) , who compared the efficacy ofhIgGl and hIgG3 chimeric mAb in antibody-dependent cellular cytotoxicity, and found a greater potency of hIgGl. Consistent with our observations, the latter study also reported this remarkable difference, in spite of a similar binding of chimeric mAb of these two subclasses to FcyR on IFN-,y treated U937 cells (44) .
Summarizing the results obtained with monocytes, PMN, and platelets, the present study suggests as subclass specificity hIgG3 > hIgGl,hIgG2 > hIgG4 for the FcyRIIa'L allotypic form, and hIgG3,hIgGl > hIgG2 > hIgG4 for the FcyRIIa'R allotypic form.
Using PMN of normal and an FcyRIII"'g donor, we analyzed whether cooperation between FcyRIIa and FcyRIII is taking place. Such cooperation has been described in functional studies of FcyRII-mediated phagocytosis (37) , immune-complex-induced PMN actin assembly (36) , and release ofhydrolytic enzymes induced by IgM anti-FcyR autoantibodies (38) . The question of potential cooperation between Fc-yR classes seems relevant in that in PNH patients who have strongly diminished expression of GPI-linked proteins, the Fc'yRIIIb expression is preserved (albeit at reduced level), likely because of a preferential assembly of GPI-anchors to FcyRIIIb compared to other GPI-linked membrane proteins (28) . This suggests that complete FcyRIIIb deficiency may be harmful. Apart from a diseased FcyRIIIb11* individual suffering from systemic lupus erythematosus (45); however, two healthy FcyRIII"* individuals have recently been described who were deficient for PMN-FcyRIIIb expression, probably because of a disruption of the structural FcyRIIIB gene (29) . We have now studied hIgG dimer interactions with PMN of one of these donors in detail. Effects of FcyRIIIb on IgG-binding by FcyRII, however, were not evident from our study (Figs. 4 and 5) . After blockade of FcyRIIIb on normal PMN, no differences were observed between normal and FcyRIII"* PMN in their ability to bind hIgGl, hIgG2, or hIgG3 dimers, which was found FcyRIIa'u-mediated. Interestingly, the efficacy of hIgGl anti-CD3-induced T cell proliferation was not affected when normal PMN were substituted by FcyRIII"9 cells and with both PMN populations, FcyRI and Fc'yRII seemed involved in sustaining T cell mitogenicity. These data raise questions about the in vivo role ofthe third class ofFcyR, and may point to a structurally redundant system. An important question regarding the functional FcyRIIa polymorphism remains: Is there an in vivo relevance? A study by Wee et al. (46) suggests a relevance in immunotherapy, in that differences in the efficacy of mIgG1 anti-CD8 induced clearing ofT cells in kidney transplant recipients were observed between HR and LR individuals. In the present study, we observed a significant correlation between hIgGi and hIgG2 serum levels, and the FcyRIIa-phenotype in healthy donors. To correct for differences in total hIgG serum levels, which vary considerably between adults (47), we calculated hIgGl and hIgG2 relative to hIgG serum levels in each individual. This seems correct since the proportion of each subclass relative to the total hIgG content is maintained within a narrow range (reviewed in [48] ). Our data suggest that FcyRIIa may in some way regulate hIgG subclass production/turnover. The mechanism behind this regulation, however, remains to be elucidated. It seems unlikely that regulation occurs via FcyRII expressed on B cells, since B cells are equipped with FcyRIIb isoforms, which do not express the HR-LR polymorphism (7, 10, 34) . In the murine system, modulation of Ig production and proliferation of B cells has been described by soluble FcR, collectively termed "IgG binding factors." Such factors were also demonstrated in human serum (39) . Recently, molecular cloning ofhuman FcyRIIa has generated cDNA clones lacking a transmembrane domain (8, 49) , these FcyR may represent putative soluble FcyRIla-molecules expressing the polymorphism. It will, therefore, be interesting to evaluate the possible role ofsoluble FcyR further with respect to the observed differences in hIgG2 serum levels found in vivo. Interestingly, hIgG2 is the main isotype induced in the humoral response after challenge with bacterial polysaccharides, and it mediates an important role in immune responses to certain capsulated bacteria, such as Streptococcus pneumoniae and Haemophilus influenzae type b. This is indicated by an increased susceptibility to these pathogens in patients with selective hIgG2 subclass deficiency (48) . On the condition that these protective properties of hIgG2 antibodies are ofcell-mediated nature, suggested by a low activity in Clq-binding and complement-mediated lysis (43) (although hIgG2 may be effective at high antigen densities [50] ), it is important to investigate whether the FcyRIIaphenotype is linked with susceptibility to bacterial infections.
